Webinar: Targeted Protein Degradation Virtual Symposium
Bio-Techne is delighted to welcome leading scientists to talk about their recent research and perspectives in the exciting, fast-moving field of Targeted Protein Degradation.
The symposium will bring together insights on:
- Critical assessment of the field
- PROTAC® design, discovery and development
- Innovative new research tools
- Expanding the E3 ligase toolbox
- We hope you will join us for what will be a fascinating and informative symposium.
Targeted Protein Degradation (TPD) is a technology that harnesses small molecule modalities (molecular glues, PROTAC® Degraders, SNIPERS etc) to achieve selective knockdown of target proteins within cells. Heterobifunctional Degraders represent an exciting new modality, repurposing small molecule ligands to achieve selective degradation (knock-down) of target proteins and offering the potential to expand the druggable proteome.
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Dr. Milka Kostic, Chemical Biology Program Director. Dana-Farber Cancer Institute
Dr. Alex Bullock, Principal Investigator, Structural Genomics Consortium. University of Oxford
Dr. Cristina Mayor-Ruiz, Post-doctoral Research Fellow. CeMM Research Center for Molecular Medicine
Dr. Behnam Nabet, Katherine Loker Pinard Fellow. Dana-Farber Cancer Institute
Dr. Fleur Ferguson, Post-doctoral Research Fellow. Dana-Farber Cancer Institute
Dr. Nicole Trainor, Project Lead Scientist for PROTAC discovery collaboration. University of Dundee and Boehringer Ingelheim
Dr. Scott Edmondson, Director and Head of Oncology Chemistry. AstraZeneca
Dr. Hannah Maple, Innovation Manager. Bio-Techne